To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants

Summary

XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management. This is a first-in-human (FIH), single-centre, double blind, randomised, SAD and MAD study of XW003 conducted in healthy adult participants. The study is designed to evaluate the safety, tolerability, PK, and PD of XW003 in healthy adult participants.

Timeline

Start

2020-03-29

Primary completion

2021-09-29

Completion

2021-09-29

Publications

• Guo W, Xu Z, Zou H, Li F, Li Y, Feng J, Zhu Z, Zheng Q, Zhu R, Wang B, Li Y, Hao S, Qin H, Jones CL, Adegbite E, Telusca L, Fenaux M, Zhong W, Junaidi MK, Xu S, Pan H. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023 Sep;75:101762. doi: 10.1016/j.molmet.2023.101762. Epub 2023 Jun 24.

Drugs

Indications